Literature DB >> 25151286

Timing of surgery in valvular heart disease: prophylactic surgery vs watchful waiting in the asymptomatic patient.

Linda D Gillam1, Leo Marcoff2, Sofia Shames3.   

Abstract

In the absence of randomized controlled trial data, the management of patients with severe valvular heart disease without symptoms, ventricular dysfunction, or other identified triggers for surgery is controversial. In this review, we frame the debate between prophylactic surgery vs close follow-up until triggers occur (watchful waiting) for severe aortic stenosis and degenerative mitral regurgitation (MR), the 2 conditions for which the pros and cons of these approaches are best articulated. Classic high-gradient severe aortic stenosis is generally accurately diagnosed. In asymptomatic patients, stress testing can be used to confirm asymptomatic status and identify high-risk features including reduced exercise tolerance, exercise-induced symptoms, and absolute or relative hypotension. Resting echocardiographic predictors of disease progression and/or adverse events include very high gradients, rapid progression, and extensive calcification. Surgical risk calculators can help estimate perioperative morbidity/mortality with the ultimate choice of a medical vs a prophylactic surgical approach to be made after discussion with the patient. With degenerative MR, severity can be inaccurately estimated. Stress testing might clarify whether the patient is truly asymptomatic and identify features associated with worse prognosis and symptom onset. Selecting patients with high probability of repair can be challenging. Perioperative risk and postoperative risks including those of unanticipated valve replacement and recurrent MR after repair are also considerations. In aggregate, management of patients with valvular disease who are asymptomatic and who have no clear trigger for surgery is complex, requires individualization, and should be carried out by or in collaboration with a heart valve centre of excellence.
Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25151286     DOI: 10.1016/j.cjca.2014.06.019

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

Review 1.  Mitral valve disease--morphology and mechanisms.

Authors:  Robert A Levine; Albert A Hagége; Daniel P Judge; Muralidhar Padala; Jacob P Dal-Bianco; Elena Aikawa; Jonathan Beaudoin; Joyce Bischoff; Nabila Bouatia-Naji; Patrick Bruneval; Jonathan T Butcher; Alain Carpentier; Miguel Chaput; Adrian H Chester; Catherine Clusel; Francesca N Delling; Harry C Dietz; Christian Dina; Ronen Durst; Leticia Fernandez-Friera; Mark D Handschumacher; Morten O Jensen; Xavier P Jeunemaitre; Hervé Le Marec; Thierry Le Tourneau; Roger R Markwald; Jean Mérot; Emmanuel Messas; David P Milan; Tui Neri; Russell A Norris; David Peal; Maelle Perrocheau; Vincent Probst; Michael Pucéat; Nadia Rosenthal; Jorge Solis; Jean-Jacques Schott; Ehud Schwammenthal; Susan A Slaugenhaupt; Jae-Kwan Song; Magdi H Yacoub
Journal:  Nat Rev Cardiol       Date:  2015-10-20       Impact factor: 32.419

2.  Is pulmonary artery pressure a trigger of adverse outcome in mitral regurgitation?

Authors:  Iside Scarfò; Giovanni La Canna
Journal:  Ann Transl Med       Date:  2016-12

Review 3.  Early surgical intervention or watchful waiting for the management of asymptomatic mitral regurgitation: a systematic review and meta-analysis.

Authors:  Andrew B Goldstone; William L Patrick; Jeffrey E Cohen; Chiaka N Aribeana; Rita Popat; Y Joseph Woo
Journal:  Ann Cardiothorac Surg       Date:  2015-05

Review 4.  Transcatheter management of severe aortic stenosis during the COVID-19 pandemic.

Authors:  Bharat Khialani; Philip MacCarthy
Journal:  Heart       Date:  2020-06-10       Impact factor: 5.994

5.  Forward Left Ventricular Ejection Fraction: A Simple Risk Marker in Patients With Primary Mitral Regurgitation.

Authors:  Marlène Dupuis; Haïfa Mahjoub; Marie-Annick Clavel; Nancy Côté; Oumhani Toubal; Lionel Tastet; Jean G Dumesnil; Kim O'Connor; Abdellaziz Dahou; Christophe Thébault; Catherine Bélanger; Jonathan Beaudoin; Marie Arsenault; Mathieu Bernier; Philippe Pibarot
Journal:  J Am Heart Assoc       Date:  2017-10-27       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.